Postpartum depression (PPD) refers to the depression that some women experience after childbirth. Very few drugs are approved to treat PPD; hence, the drugs used for major depressive disorder (e.g., SSRIs, SNRIs, mixed serotonin modulators, atypical antipsychotics) are often used off-label for PPD. The high unmet need for therapies specifically targeting PPD gives the first agent approved to treat the disorder, Zulresso (Sage Therapeutics), an opportunity to be incorporated into the PPD treatment algorithm and creates opportunities for the new oral drug Zurzuvae (Sage Therapeutics) and for future drug developers. This report provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current PPD treatment landscape.
Questions answered
Markets covered: United States
Key companies: Sage Therapeutics, AbbVie, Lundbeck, Otsuka, Takeda, Johnson & Johnson Innovative Medicine, Axsome Therapeutics
Key drugs: Zulresso, SSRIs, SNRIs, bupropion, atypical antipsychotics, mixed serotonin modulators, tricyclic antidepressants, benzodiazepines, anxiolytics
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key features
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.